1. Home
  2. NMFC vs PCRX Comparison

NMFC vs PCRX Comparison

Compare NMFC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMFC
  • PCRX
  • Stock Information
  • Founded
  • NMFC 2010
  • PCRX 2006
  • Country
  • NMFC United States
  • PCRX United States
  • Employees
  • NMFC N/A
  • PCRX N/A
  • Industry
  • NMFC Finance/Investors Services
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NMFC Finance
  • PCRX Health Care
  • Exchange
  • NMFC Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • NMFC 1.2B
  • PCRX 1.2B
  • IPO Year
  • NMFC 2011
  • PCRX 2011
  • Fundamental
  • Price
  • NMFC $10.59
  • PCRX $22.55
  • Analyst Decision
  • NMFC Hold
  • PCRX Buy
  • Analyst Count
  • NMFC 3
  • PCRX 8
  • Target Price
  • NMFC $11.00
  • PCRX $28.38
  • AVG Volume (30 Days)
  • NMFC 366.7K
  • PCRX 530.9K
  • Earning Date
  • NMFC 08-04-2025
  • PCRX 08-05-2025
  • Dividend Yield
  • NMFC 12.38%
  • PCRX N/A
  • EPS Growth
  • NMFC N/A
  • PCRX N/A
  • EPS
  • NMFC 0.99
  • PCRX N/A
  • Revenue
  • NMFC $366,773,000.00
  • PCRX $702,772,000.00
  • Revenue This Year
  • NMFC N/A
  • PCRX $7.92
  • Revenue Next Year
  • NMFC N/A
  • PCRX $11.02
  • P/E Ratio
  • NMFC $10.69
  • PCRX N/A
  • Revenue Growth
  • NMFC N/A
  • PCRX 3.08
  • 52 Week Low
  • NMFC $8.84
  • PCRX $11.16
  • 52 Week High
  • NMFC $12.55
  • PCRX $27.64
  • Technical
  • Relative Strength Index (RSI)
  • NMFC 47.99
  • PCRX 43.85
  • Support Level
  • NMFC $10.56
  • PCRX $21.26
  • Resistance Level
  • NMFC $10.78
  • PCRX $22.95
  • Average True Range (ATR)
  • NMFC 0.14
  • PCRX 0.83
  • MACD
  • NMFC -0.01
  • PCRX 0.01
  • Stochastic Oscillator
  • NMFC 8.82
  • PCRX 48.68

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: